Company overview
What does SUPERNUS PHARMACEUTICALS, INC. do?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 2834 (Pharmaceutical Preparations).
What does SUPERNUS PHARMACEUTICALS, INC. do?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 2834 (Pharmaceutical Preparations).
What industry is SUPERNUS PHARMACEUTICALS, INC. in?
Biotechnology · Pharmaceutical Preparations
What was SUPERNUS PHARMACEUTICALS, INC.'s latest reported revenue?
$219.1M for Q2 2026, from 10-Q filed Aug 3, 2026.
What changed in the latest comparable period?
Revenue increased +32.4% ($165.5M to $219.1M; Q2 2025 vs Q2 2026).
Business model (from the public record)
Belvedere describes the business using the issuer’s SEC classification and the company description extracted from public filings. Segment mix, customer identity, and recurring-versus-transactional revenue are shown only when those facts are identified in the filing extract—not inferred.
Biotechnology · Pharmaceutical Preparations · United States
Financial profile
- Revenue
- $219.1M 10-Q · Q2 2026 · Filed Aug 3, 2026
- Revenue growth YoY
- +32.4% Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 3, 2026
- Gross margin
- +84.6% Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 3, 2026
- Operating margin
- -26.5% Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 3, 2026
- Net income
- -$58.4M 10-Q · Q2 2026 · Filed Aug 3, 2026
- Operating cash flow
- — Not identified in latest matched XBRL period
- Capex
- — Not identified in latest matched XBRL period
- Belvedere FCF
- — Not identified in latest matched XBRL period
- FCF margin
- — Not identified in latest matched XBRL period
- Cash
- $180M 10-Q · Jun 30, 2026 · Filed Aug 3, 2026
- Debt
- — Not identified in latest matched XBRL period
- Net debt
- -$180M Belvedere calculation · 10-Q · Jun 30, 2026 · Filed Aug 3, 2026
- Shares
- 58,164,352 10-Q · Jun 30, 2026 · Filed Aug 3, 2026
Balance sheet snapshot
Cash $180M. Identified debt —. Net debt -$180M. Missing debt tags are not treated as a zero-debt capital structure.
Financial information is derived from public filings and other identified sources. Belvedere calculations may differ from company-defined non-GAAP measures. See methodology and source notes. Valuation multiples are omitted because a licensed market-data provider is not configured.
Latest filings
| Form | Filed | Period | Accession | Source |
|---|---|---|---|---|
| 8-K | Aug 3, 2026 | Aug 3, 2026 | 0001104659-26-089839 | SEC |
| 8-K | Aug 3, 2026 | Aug 3, 2026 | 0001104659-26-089524 | SEC |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | 0001356576-26-000037 | SEC |
| 8-K | Aug 3, 2026 | Aug 3, 2026 | 0001356576-26-000035 | SEC |
| 8-K | Aug 3, 2026 | Aug 1, 2026 | 0001104659-26-089425 | SEC |
| 8-K | Jul 22, 2026 | Jul 22, 2026 | 0001356576-26-000031 | SEC |
| 8-K | Jun 18, 2026 | Jun 18, 2026 | 0001356576-26-000028 | SEC |
| 8-K | May 20, 2026 | May 17, 2026 | 0001356576-26-000025 | SEC |
| 10-Q | May 5, 2026 | Mar 31, 2026 | 0001356576-26-000022 | SEC |
| 8-K | May 5, 2026 | May 5, 2026 | 0001356576-26-000020 | SEC |
| DEF 14A | Apr 30, 2026 | Jun 18, 2026 | 0001104659-26-053111 | SEC |
| 8-K | Apr 22, 2026 | Apr 22, 2026 | 0001356576-26-000015 | SEC |
| 8-K | Apr 7, 2026 | Apr 1, 2026 | 0001104659-26-040497 | SEC |
What changed
Each line is an arithmetic comparison of sourced facts. It is not a thesis.
Research view
Belvedere has not published an initiation or update on SUPERNUS PHARMACEUTICALS, INC.. Universe inclusion is not a rating, a forecast, or coverage in the sell-side sense.
Research Radar
| Kind | Change | Explanation | Source | Date |
|---|---|---|---|---|
| Revenue | +32.4% | Revenue increased +32.4% ($165.5M to $219.1M; Q2 2025 vs Q2 2026). | 10-Q · RevenueFromContractWithCustomerExcludingAssessedTax | Aug 3, 2026 |
| Revenue acceleration | -6.2 pp | Quarterly revenue YoY growth moved from +38.6% to +32.4% (-6.2 percentage points). | 10-Q · BelvedereRevenueGrowthYoY | Aug 3, 2026 |
| Margin change | $0.846 | Reported gross margin was +84.6% in the latest comparable period. | 10-Q · BelvedereGrossMargin | Aug 3, 2026 |
| Cash | $180.0M | Cash and cash equivalents were $180.0M as of the latest reported balance-sheet date. | 10-Q · CashAndCashEquivalentsAtCarryingValue | Aug 3, 2026 |
| Share count | $58.2M | Shares outstanding were 58,164,352 as of the latest reported date. | 10-Q · CommonStockSharesOutstanding | Aug 3, 2026 |
Rankings
- Fastest-Growing Companies in the Belvedere Universe · rank 10 · +32.4%
- Strongest Balance Sheets · rank 44 · +12.6%
- Healthcare Companies by Revenue Growth · rank 1 · +32.4%
Industry context
SUPERNUS PHARMACEUTICALS, INC. is mapped to Biotechnology (Pharmaceutical Preparations) from SIC metadata on the SEC submission. Mapping is a classification convenience, not a claim that every peer is economically comparable.
Belvedere Research Profile
This measures researchable information characteristics. It is not investment advice, a credit rating, or a buy/sell/hold recommendation.
Presence of core income-statement, cash-flow and balance-sheet concepts in SEC XBRL.
Comparable-period revenue history and operating-result availability.
Availability of margin, cash-flow and per-share concepts used in screening.
SEC periodic reports, current reports, proxy statement and website identified in submissions.
Distinct filing years in the current archive window plus comparable prior-period revenue.
Risks
Belvedere does not manufacture generic risk language. Material risks are those the issuer discloses in its periodic reports, particularly Item 1A of the latest Form 10-K.
A Form 10-K was not present in the current filing window.
Sources
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Aug 3, 2026
- Accession
- 0001356576-26-000037
- Concept
- RevenueFromContractWithCustomerExcludingAssessedTax
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Aug 3, 2026
- Accession
- 0001356576-26-000037
- Concept
- BelvedereRevenueGrowthYoY
(RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30 / RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30) - 1
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Jun 30, 2026
- Filed
- Aug 3, 2026
- Accession
- 0001356576-26-000037
- Concept
- CashAndCashEquivalentsAtCarryingValue
Disclosure
Belvedere Research publishes informational analysis. Nothing on this site is investment advice, an offer, or a solicitation to buy or sell any security.
This page is a company intelligence / data profile. It is not a research report unless a dated note is attached above. Rankings appearing here are independent of any issuer compensation.
Frequently asked questions
- What does SUPERNUS PHARMACEUTICALS, INC. do?
- SUPERNUS PHARMACEUTICALS, INC. (SUPN) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 2834 (Pharmaceutical Preparations).
- What industry is SUPERNUS PHARMACEUTICALS, INC. in?
- SUPERNUS PHARMACEUTICALS, INC. is classified in Biotechnology (Pharmaceutical Preparations).
- When did SUPERNUS PHARMACEUTICALS, INC. last file a periodic report?
- SUPERNUS PHARMACEUTICALS, INC. last filed a 10-Q on Aug 3, 2026 (accession 0001356576-26-000037).
- What was SUPERNUS PHARMACEUTICALS, INC.'s latest revenue?
- $219.1M for Q2 2026, sourced from 10-Q filed Aug 3, 2026.
- Does Belvedere cover SUPERNUS PHARMACEUTICALS, INC.?
- SUPERNUS PHARMACEUTICALS, INC. is in the Belvedere universe. Presence in the universe is not the same as active initiation coverage.